Please wait while we open this resource.
K
Clinical reviews
Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial
University Medical Center Utrecht
PDF11 pages4.0 MB
The RepurpSS-II trial investigated the combination therapy of leflunomide and hydroxychloroquine for Sjögren's disease, a condition characterized by secretory gland dysfunction lacking effective systemic treatment. The study involved adult patients with a specific ESSDAI score, randomly assigned to receive either the drug combination or a placebo. The primary endpoint was the change in ESSDAI from baseline to 24 weeks, with analyses conducted on the intention-to-treat population. The trial was registered and completed.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
EARLY TRAUMA AS THE ORIGIN OF CHRONIC INFLAMMATION: A PSYCHONEUROIMMUNOLOGICAL PERSPECTIVE
Same clinical topic · Rheumatology
IDIOPATHIC INFLAMMATORY MYOPATHIES
Same clinical topic · Rheumatology
MULTIFACTORIAL PATHOGENESIS OF RHEUMATOID ARTHRITIS
Same clinical topic · Rheumatology
SYSTEMIC LUPUS ERYTHEMATOSUS IN CRITICAL CARE: A SYSTEMATIC REVIEW OF ICU OUTCOMES AND MANAGEMENT
Same clinical topic · Rheumatology
RHEUMATOID ARTHRITIS — COMMON ORIGINS, DIVERGENT MECHANISMS
Same clinical topic · Rheumatology
RHEUMATOID ARTHRITIS IN ADULTS
Same clinical topic · Rheumatology
BIOLOGICAL THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Same clinical topic · Rheumatology
SYSTEMIC LUPUS ERYTHEMATOSUS: DIAGNOSIS AND TREATMENT
Same clinical topic · Rheumatology
SYSTEMIC LUPUS ERYTHEMATOSUS: NEW DIAGNOSTIC AND THERAPEUTIC APPROACHES
Same clinical topic · Rheumatology